financetom
Business
financetom
/
Business
/
IndiGo dispute: Read the full text of Rakesh Gangwal's letter to directors
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IndiGo dispute: Read the full text of Rakesh Gangwal's letter to directors
Aug 6, 2019 1:13 AM

IndiGo co-founder Rakesh Gangwal has written a letter to the board of directors of InterGlobe Aviation, reiterating that there are still disagreements between him and Rahul Bhatia's InterGlobe Enterprises (IGE) on related-party transaction (RPT) policy and board composition. "I again reiterate that I am no longer in a position to vote affirmatively on the special resolution for alteration in articles of association of the company," unless as discussed in numerous emails (I) a complementary board resolution is passed to prevent IGE group from getting even more rights and abilities than they have today (ii) the new RPT policy is adopted, language for which has already been agreed," Gangwal said in the letter dated August 5.

Here is the full text of the letter sent by Gangwal to directors:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Beyond Meat Stock Surges After Debt Swap: No Bankruptcy, But Tons of Dilution
Beyond Meat Stock Surges After Debt Swap: No Bankruptcy, But Tons of Dilution
Oct 20, 2025
After a year of financial strain and fear of insolvency, Beyond Meat, Inc. ( BYND ) surprised the market with a sudden rally on Monday — even as it handed most of the company over to its bondholders.  BYND stock is soaring. See the real-time price action here.  Debt Swap Beyond Meat ( BYND ) stock surged more than 24% after...
Jazz Pharmaceuticals Has Upside Potential in Oncology Pipeline Revenue, Morgan Stanley Says
Jazz Pharmaceuticals Has Upside Potential in Oncology Pipeline Revenue, Morgan Stanley Says
Oct 20, 2025
09:00 AM EDT, 10/20/2025 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) is tracking well for a meaningful expansion opportunity for its Ziihera beyond biliary tract cancer into gastroesophageal adenocarcinoma, Morgan Stanley said in a note Sunday. Analysts at Morgan Stanley added that the balance sheet strategy and business development execution is critical to support the terminal value. Jazz is...
Greenlane Renewables Files Patent Application For Linear Nitrogen Rejection Technology
Greenlane Renewables Files Patent Application For Linear Nitrogen Rejection Technology
Oct 20, 2025
08:59 AM EDT, 10/20/2025 (MT Newswires) -- Greenlane Renewables ( GRNWF ) said Monday it has filed a new patent application for a Linear Nitrogen Rejection Unit (NRU) as part of its Cascade LF product line, the company's newest landfill gas upgrading technology. According to a statement, the Linear NRU allows the Cascade LF to achieve even higher methane recovery...
Halozyme Therapeutics' Royalty Growth and Cost Control to Drive Q3 Earnings, Morgan Stanley Says
Halozyme Therapeutics' Royalty Growth and Cost Control to Drive Q3 Earnings, Morgan Stanley Says
Oct 20, 2025
09:00 AM EDT, 10/20/2025 (MT Newswires) -- Halozyme Therapeutics' ( HALO ) strength in royalty revenues and cost discipline will drive Q3 earnings, Morgan Stanley said in a note Monday. Morgan Stanley expects Q3 revenue of $346 million and diluted earnings of $1.47 per share, both slightly above consensus estimates. Halozyme's revenue and earnings should benefit from its Enhanze platform,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved